The medical treatment of Parkinson disease from James Parkinson to George Cotzias

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 4-18

  Fahn, Stanley ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Alkaloids; Antimuscarinics; dl dopa; Dopamine; l dopa; Reserpine

Indexed keywords

ALKALOID DERIVATIVE; LEVODOPA; MUSCARINIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT;

BIOCHEMISTRY; CELL LOSS; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG USE; HUMAN; LOW DRUG DOSE; NERVE CELL; NIGRAL NEURON; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCIENCE; STRIATAL DOPAMINE DEFICIENCY; ANIMAL; HISTORY; MALE; NEUROLOGY;

ANIMALS; ANTIPARKINSON AGENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; NEUROLOGY; PARKINSON DISEASE;

EID: 84920870609     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26102     Document Type: Review

References (147)

1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817.
2. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007;130:2123-2128.
3. Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord 1990;5:47-48.
4. Foley PB. Beans, Roots and Leaves. A History of the Chemical Therapy of Parkinsonism. Marburg, Germany : Tectum Verlag ; 2002.
5. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008;23(Suppl 3):S497-S508.
6. Fahn S, Duffy P. Parkinson's disease. In: Goldensohn ES, Appel SH, eds. Scientific Approaches to Clinical Neurology. Philadelphia, PA: Lea & Febiger; 1977:1119-1158.
7. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
8. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
9. Elliotson J. Paralysis agitans. Lancet 1830;1:119-124.
10. Thompson JB. "Chorea sancti vitis", with cases and observations. Lancet 1842;1:616-618.
11. Sanders W. Case of an unusual form of nervous disease, dystaxia or pseudo-paralysis agitans, with remarks. Edinburgh Med J 1865;10:987-997.
12. Romberg MH. A Manual on the Nervous Diseases of Man, vol II, translated by Sieveking EH. London: The Sydenham Society; 1853:234.
13. Duchenne du Boulogne GBA. De l'électrisation localisée, et de son application à la pathologie et à la thérapeutique [A treatise on localized electrization, and its applications to pathology and therapeutics]. Paris: J.B. Ballière; 1855.
14. Erb WH. Handbook of Electrotherapeutics, translated by Pützel L. New York: William Woods; 1883.
15. Gowers WR. A Manual of Diseases of the Nervous System, Vol. II, 2nd ed. Philadelphia, PA: Blakiston; 1893:656.
16. Hammond WA. A Treatise on Diseases of the Nervous System. New York: D. Appleton; 1871:709-710.
17. Goetz CG. Jean-Martin Charcot and his vibratory chair for Parkinson disease. Neurology 2009;73:475-478.
18. Kapur SS, Stebbins GT, Goetz CG. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis 2012;2:23-27.
19. Goetz CG. Charcot, the C!inician: the Tuesday Lessons. Excerpts from Nine Case Presentations on General Neurology Delivered at the Salpêtriere Hospital in 1887-88 By Jean-Martin Charcot, translated with commentary. New York: Raven; 1987:123.
20. Ordenstein L. Sur la paralsie agitante et la sclérose en plaques généralisées [On paralysis agitans and multiple sclerosis]. Paris: Delahaye; 1868.
21. Lehmann HC, Hartung HP, Kieseier BC. Leopold Ordenstein: on paralysis agitans and multiple sclerosis. Mult Scler 2007;13:1195-1199.
22. Erb WH. Über Hyoscin [About hyoscine]. Therap Monatshefte 1887;1:252-254.
23. Mendel E. Über Duboisin [About duboisine]. Neurol Centralbl 1893;12:89-93.
24. Oppenheim H. Zur Diagnose, Prognose und Therapie der Paralysis agitans [Toward the diagnosis, prognosis and treatment of paralysis agitans]. Klinischer Vortrag. Dtsch med Wschr 1905;31:1705-1710.
25. Oppenheim H. Textbook of Nervous Diseases for Physicians and Students, 5th ed., translated by Bruce A. Edinburgh, UK: Otto Schulzle; 1911:1310.
26. Jelliffe SE, White WA. Diseases of the Nervous System. Philadelphia, PA: Lea & Febiger; 1923:626.
27. Wechsler IS. A Textbook of Clinical Neurology, 2nd ed. Philadelphia, PA: W.B. Saunders; 1932:579.
28. Wilson SAK. Neurology, Vol. II. Baltimore, MD: Williams & Wilkins; 1940:804-805.
29. Feldberg W. Present views on the mode of action of acetylcholine in the central nervous system. Physiol Rev 1945;25:596-542.
30. Schwab RS, Leigh D. Parpanit in the treatment of Parkinson's disease. J Am Med Assoc 1949;139:629-634.
31. Doshay LJ, Constable K. Newer drugs in the treatment of parkinsonism. Neurology 1951;1:68-74.
32. Doshay LJ, Constable K. Artane therapy for parkinsonism; a preliminary study of results in 117 cases. J Am Med Assoc 1949;140:1317-1322.
33. Corbin KB. Trihexyphenidyl; evaluation of the new agent in the treatment of Parkinsonism. J Am Med Assoc 1949;141:377-382.
34. Schwab RS, Tillmann WR. Artane in the treatment of Parkinson's disease; a report of its effectiveness alone and in combination with benadryl and parpanit. N Engl J Med 1949;241:483-485.
35. Doshay LJ, Constable K, Zier A. Five year follow-up of treatment with trihexyphenidyl (Artane); outcome in four hundred eleven cases of paralysis agitans. J Am Med Assoc 1954;154:1334-1336.
36. Garai O. Lysivane and artane in the treatment of parkinsonism. Lancet 1951;1:429-432.
37. Doshay LJ, Zier A. Drug therapy. In: Doshay LJ, ed. Parkinsonism and Its Treatment. Philadelphia, PA: J.B. Lippincott; 1954:77-102.
38. Halliday AM, Nathan PW. Methyl phenidate in parkinsonism. Br Med J 1961;1:1652-1655.
39. England AC, Jr., Schwab RS. The management of Parkinson's disease. Arch Intern Med 1959;104:439-468.
40. Budnitz J. The use of benadryl in Parkinson's disease; a preliminary report of eight cases. N Engl J Med 1948;238:874.
41. Doshay LJ, Constable K. Treatment of paralysis agitans with orphenadrine (disipal) hydrochloride; results in one hundred seventy-six cases. J Am Med Assoc 1957;163:1352-1357.
42. Pearce JMS. Samuel Jones Gee (1839-1911) and stereotypic movements caused by apomorphia. J Neurol Neurosurg Psychiat 1995;59:279.
43. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;56:251-253.
44. Schwab RS, England AC, Jr. Problems in the treatment of Parkinsonism by analeptics. Trans Am Neurol Assoc 1956;(81st Meeting):51-57.
45. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med 1976;294:567-572.
46. Barger G, Ewins AJ. Some phenolic derivatives of β-phenylethylamine. J Chem Soc 1910;97:2253-2261.
47. Mannich C, Jacobsohn W. Über Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine [Oxyphenyl alkylamine and dioxyphenyl alkylamine]. Ber dtsch chem Ges 1910;43:189-197.
48. Shepherd DM, West GB. Hydroxytyramine and the adrenal medulla. J Physiol 1953;120:15-19.
49. Shepherd DM, West GB. Hydroxytyramine (dopamine) and the suprarenal medulla. J Physiol 1952;117:67P-68P.
50. Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. J Physiol 1910;41:19-59.
51. Funk C. Synthesis of dl-3:4-dihydroxyphenylalanine. J Chem Soc 1911;99:554-557.
52. Griminger P. Casimir Funk-a biographical sketch (1884-1967). J Nutr 1972;102:1105-1113.
53. Guggenheim M. Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Zschr physiol Chem 1913;88:276-284.
54. Waser E, Lewandowski M. Untersuchungen in der Phenylalanin-Reihe I. Synthese des l-3, 4-Dioxy-phenylalanins [Studies on the phenylalanine series. I. Synthesis of L-3, 4-dihydroxyphenylalanine]. Helv chim Acta 1921;4:657-666.
55. Blaschko H, Richter D, Schlossmann H. The inactivation of adrenaline. J Physiol 1937;90:1-17.
56. Holtz P, Reinhold A, Credner K. Fermentativer Abbau von l-Dioxyphenylalanin (Dopa) durch Leber und Darm [Enzymatic break down of L-dihydroxyphenylalanine (dopa) in the liver and intestine]. Zschr Physiol Chem 1939;261: 278-286.
57. Holtz P. Dopadecarboxylase. Naturwissenechaften 1939;27:724-725.
58. Blaschko H. The specific action of l-dopa decarboxylase. J Physiol 1939;96:50P-5lP.
59. Von Euler US. The nature of adrenergic nerve mediators. Pharmacol Rev 1951;3:247-277.
60. Goodall M. Studies of adrenaline and noradrenaline in mammalian heart and suprarenals. Acta Physiol Scand Suppl 1951;24:7-51.
61. Schümann HJ. [Determination of hydroxytyramine (dopamine) in sympathetic nerves and ganglia]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1956;227:566-573.
62. Von Euler US, Hellner S. Excretion of noradrenaline, adrenaline, and hydroxytyramine in urine. Acta Physiol Scand 1951;22:160-167.
63. Holtz P, Bachmann F. Activierung der Dopadecarboxylase des Nebennierenmarks durch Nebennieren-Rindenextrakt [Activation of porcine adrenal dopa decarboxylase by bovine adrenal extract]. Naturwissenachaften. 1952;39:116-117.
64. Duvoisin RC, Yahr MD, Coté LD. Pyridoxine reversal of L-dopa effects in parkinsonism. Trans Am Neurol Assoc 1969;94:81-84.
65. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431-441.
66. Blaschko H, Welch AD. Localization of adrenaline in cytoplasmic particles of the bovine adrenal medulla. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1953;219:17-22.
67. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002;17:501-508.
68. Hornykiewicz O. The action of dopamine on the arterial pressure of the guinea pig. Br J Pharmacol 1958;13:91-94.
69. Raper HS. The tyrosinase-tyrosine reaction: production of l-3.4-dihydroxyphenylalanine from tyrosine. Biochem J 1926;20:735-742.
70. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis. J Biol Chem 1964;239:2910-1917.
71. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase 1 gene. Nat Genet 1994;8:236-242.
72. Shaw KN, McMillan A, Armstrong MD. The metabolism of 3, 4-dihydroxyphenylalanine. J Biol Chem 1957;226:255-266.
73. Muller JM, Schlittler E, Bein HJ. Reserpin, der sedative Werkstoff aus Rauwolfia serpentina Benth [Reserpine, the sedative principle from Rauwolfia serpentina B]. Experientia 1952;8:338-338.
74. May RH, Voegele GE. Parkinsonian reactions following chlorpromazine and reserpine; similar reactions in the same patients. AMA Arch Neurol Psychiatry 1956;75:522-524.
75. Pletscher A, Shore PA, Brodie BB. Serotonin release as a possible mechanism of reserpine action. Science 1955;122:374-375.
76. Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 2002;109:777-787.
77. Carlsson A, Shore PA, Brodie BB. Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther 1957;120:334-339.
78. Holzbauer M, Vogt M. Depression by reserpine of the noradrenaline concentration in the hypothalamus of the cat. J Neurochem 1956;1:8-11.
79. Lees AJ, Tolosa E, Olanow CW. Four pioneers establishing levodopa as therapy for Parkinson disease. Part 1. Arvid Carlsson. A determined free radical. Mov Disord This issue.
80. Carlsson A. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand 1958;44:295-298.
81. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200.
82. Carlsson A, Lindqvist M, Magnusson T. On the biochemistry and possible function of dopamine and noradrenaline in the brain. In: Vame JR, Wolstenholme GEW, O'Connor M, eds. CIBA Foundation jointly with Committee for Symposia on Drug Action on Adrenergic Mechanisms. London: J & A Churchill; 1960:432-439.
83. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel Lecture, December 8, 2000. In: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2000/carlsson-lecture.pdf.
84. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958;127:471.
85. Bertler A, Rosengren E. Occurrence and distribution of catechol amines in brain. Experientia 1959;15:10-11.
86. Sano I, Gamo T, Kakimoto Y Taniguchi K, Takesada M, Nishinuma K. Distribution of catechol compounds in human brain. Biochim Biophys Acta 1959;32:586-587.
87. Bertler A, Rosengren E. On the distribution in brain of monoamines and of enzymes responsible for their formation. Experientia 1959;15:382-384.
88. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959:11:490-493.
89. Ehringer H, Hornykiewicz O: Verteilung von Noradrenalin und Dopamin (3-Hydroxytryamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr 1960;38:1238-1239. (English translation can be found in Parkinsonism Relat Disord 1998;4:53-57.).
90. Sano H (sic) (first name is actually Isamu). Biochemistry of the extrapyramidal system. Parkinsonism Relat Disord 2000;6:3-6. [English translation from original in Shinkei Kennkyu No Shinpo (Advances in Neurological Sciences) 1960;5:42-48.).
91. Hornykiewicz O. [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. Wien Klin Wochenschr 1963;75:309-312.
92. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth Scientific; 1982;41-58.
93. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-964.
94. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
95. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715-725.
96. Falck B, Hillarp NA, Thieme G, Torp A. Fluorescence of catechol amines and related compound condensed with formaldehyde. J Histochem Cytochem 1962;10348-10354.
97. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964;20:398-399.
98. Anden NE, Carlsson A, Dahlstrom A, Fuxe K, Hillarp NA, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 1964;3:523-530.
99. Anden NE, Dahlstrom A, Fuxe K, Larsson K. Mapping out of catecholamine and 5-hydroxytryptamine neurons innervating the telencephalon and diencephalon. Life Sci 1965;4:1275-1279.
100. Fuxe K, Anden NE. Studies on central monoamine neurons with special reference to the nigro-neostriatal dopamime neuron system. In: Costa E, Côté LJ, Yahr MD, eds. Biochemistry and Pharmacology of the Basal Ganglia. Proceedings of the Second International Symposium Sponsored by the Parkinson's Disease Information and Research Center, College of Physicians and Surgeons, Columbia University. Hewlett, NY: Raven; 1966:123-129.
101. Poirier L, Sourkes TL. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 1965;88:181-192.
102. Sourkes TL, Poirier L. Influence of the substantia nigra on the concentration of 5-hydroxytryptamine and dopamine of the striatum. Nature 1965;207:202-203.
103. Birkmayer W, Hornykiewicz O. Der L-3, 4-Dioxyphenylalanin (DOPA)-Effekt bei der Parkinson-Akinese. [The effect of L-3, 4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism.] Wien Klin Wochenschr 1961;73:787-788. (English translation available in Parkinsonism Relat Dis 1998;4:59-69.).
104. Oster KA, Sorkin SZ. Effects of intravenous injections of l-dopa upon blood pressure. Proc Soc Exp Biol Med 1942;51:67-70.
105. Holtz P, Credner K. Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopadecarboxylase [The enzymatic origin of oxytyramine in organisms and the physiological meaning of dopa decarboxylase]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1942;200:356-388.
106. Degkwitz R, Frowein R, Kulenkampff C, Mohs U. Über die Wirkungen des L-DOPA beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6. [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]. Klin Wochenschr 1960;38:120-123.
107. McGeer PL, Boulding JE, Gibson WC, Foulkes RG. Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA 1961;177:665-670.
108. Birkmayer W, Hornykiewicz O. [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1962;203:560-574.
109. Bernheimer H, Birkmayer W, Hornykiewicz O. [Behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors]. Wien Klin Wochenschr 1962;74:558-559.
110. Birkmayer W, Hornykiewicz O. Weitere experimentelle Untersuchungen űber L-DOPA beim Parkinson-Syndrom und Reserpin-Parkinsonismus. [Additional experimental studies on L-dopa in Parkinson's syndrome and reserpine parkinsonism]. Arch Psychiatr Nervenkr 1964;206:367-381.
111. Barbeau A, Sourkes TL, Murphy GF. Les catecholamines dans la maladie de Parkinson [Catecholamines in Parkinson's disease]. In: de Ajuriaguerra J, ed. Symposium Sur les Monoamines et Systeme Nerveux Central. Geneve: Georg & Cie; 1962:247-262.
112. Gerstenbrand F, Pateisky K. [Contribution to the therapy and rehabilitation of Parkinson's syndrom]. Wien Z Nervenheilkd Grenzgeb 1963;21:124-131.
113. Gerstenbrand F, Pateisky K, Prosenz P. [Experiences with L-dopa in the therapy of parkinsonism]. Psychiatr Neurol (Basel) 1963;146:246-261.
114. Friedhoff AJ, Hekiman L, Alpert M, Tobach E. Dihydroxyphenylalanine in extrapyramidal disease. JAMA 1963;184:285-286.
115. Umbach W, Bauman D. Die Wirksamkeit von L-Dopa bei Parkinson-Patienten mit und ohne sterotaktischen Herneingriff [Effectiveness of L-dopa in Parkinson patients with and without stereotaxic brain surgery]. Arch Psychiat Nervenkr 1964;205:281.
116. Hirschmann J, Mayer K. Zur Beeinflussung von L-Dopa (L-Dihydroxyphenylananin) [On the control of akinesia and other extrapyramidal motor disorders with L-dopa (L-dihydroxyphenylalanine)]. Deutsch Med Wschr 1964;89:1877-1880.
117. Greer M, Williams CM. Dopamine metabolism in Parkinson's disease. Neurology 1963;13:73-76.
118. Rinaldi F, Marghertia G, De Divitus E. Effetti della somministrazione de DOPA a pazienti parkinsoniani pretrattati con inhibitore delle monoaminossidasi [Effects from the administration of Dopa to parkinsonian patients pretreated with monoamine oxidase inhibitors]. Ann Fren Scienze Affini 1965;78:105-113.
119. Fazzagli A, Amaducci L. La Sperimentazione clinica del Dopa nelle sindromi parkinsoniane [Clinical experimentation of Dopa in parkinsonian syndromes]. Riv Neurobiol 1966;12:138-145.
120. Aebert K. Was leistet L-DOPA bei der Behandlung der Parkinson-Akinese? [What success does L-Dopa have in the treatment of parkinsonian akinesia?] Deutsch Med Wschr 1967;92:483-487.
121. Fehling C. Treatment of Parkinson's syndrome with L-DOPA, a double-blind study. Acta Neurol Scand 1966;42:367-372.
122. Rinne UK, Sonninen V. A double-blind study of L-dopa treatment in Parkinson's disease. Europ Neurol 1968;1:180-191.
123. McGeer PL, Zeldowicz LR. Administration of dihydroxyphenylalanine to parkinsonian patients. Can Med Assoc J 1964;90:463-466.
124. Duvoisin RC. A review of drug therapy in parkinsonism. Bull N Y Acad Med 1965;41:898-910.
125. Hornykiewicz O. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In: Costa E, Côté LJ, Yahr MD, eds. Biochemistry and Pharmacology of the Basal Ganglia. Hewlett, NY: Raven; 1966:171-185.
126. Cotzias GC, Papavasiliou PS, Van Woert MH, Sakamoto A. Melanogenesis and exrpyramidal diseases. Fed Proc 1964;23:713-718.
127. Yahr MD, Duvoisin RC. Drug therapy of the extrapyramidal disorders. In: Vinken PJ, Bruyn GW, eds. Diseases of the Basal Ganglia. Handbook of Clinical Neurology. Amsterdam: North-Holland Publishing Co; 1968:826-843.
128. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
129. Klawans HL, Jr., Garvin JS. Treatment of parkinsonism with L-dopa (study of 105 patients). Dis Nerv Syst 1969;30:737-746.
130. Calne DB, Stern GM, Spiers AS, Laurence DR. L-dopa in idiopathic parkinsonism. Lancet 1969;2:973-976.
131. Mones RJ, Elizan TS, Siegel GJ. Evaluation of L-dopa therapy in Parkinson's disease. N Y State J Med 1970;70:2309-2318.
132. Mawdsley C. Treatment of Parkinsonism with Laevo-dopa. Br Med J 1970;1:331-337.
133. Rinne UK, Sonninen V, Siirtola T. L-Dopa treatment in Parkinson's disease. Eur Neurol 1970;4:348-369.
134. Schwarz GA, Fahn S. Newer medical treatment in parkinsonism. Med Clin N Am 1970;54:773-785.
135. McDowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, Kessler JT. Treatment of Parkinson's syndrome with dihydroxyphenylalanine (levodopa). Ann Int Med 1970;72:29-35.
136. Kofman O. Treatment of Parkinson's disease with L-dopa: a current appraisal. Can Med Assoc J 1971;104:483-487.
137. Treciokas LJ, Ansel RD, Markham CH. One to two year treatment of Parkinson's disease with levodopa. Calif Med 1971;114:7-14.
138. Nakano KK, Tyler HR. A double-blind study of the effects of levodopa in Parkinson's disease. Neurology 1971;21:1069-1074.
139. Fehling C. Treatment of Parkinson's syndrome with L-DOPA on an out-patient basis. Z Neurol 1972;202:197-208.
140. News Item. Parkinsonism: L-Dopa goes commercial. Chem Eng News 1970:48:12.
141. Schwab RS, England AC, Jr., Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969;208:1168-1170.
142. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975;25:695-700.
143. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br Med J 1974;4:442-444.
144. Kieburtz K, Shoulson I, McDermott M, et al.; Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997;278:125-130.
145. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-1062.
146. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease-a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
147. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.